A deficit survival analysis to assess the natural history of uveal melanoma

Philip T. Lavin, Daniel Albert, Johanna M. Seddon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A deficit survival analysis was conducted using a retrospective series of 230 patients with uveal melanoma. All underwent enucleation as primary treatment for their disease. Considering the three leading prognostic factors (epithelioid cells per high power field, tumor size, and tumor location), median age was plotted against median survival to determine pathways of disease spread, local and metastatic disease phases, consequences of delayed diagnosis, and the timing of enucleation. The subgroup with all three factors favorable could be subdivided into younger and older subsets on the basis of a bimodal age distribution. Only the older subset could be identified as a local disease state where survival following enucleation corresponded to normal population survival. All remaining subgroups were metastatic because of survival deficits compared to the normal population. Disease tended to progress according to three well defined pathways with 6-8 years required to progress from one subgroup to the next along these paths. These pathways were characterized by constant deficit survivals, suggesting that delays in diagnosis did not translate into loss in survival. Moreover, the value of enucleation as primary therapy can be questioned in the context that it does not appear to alter the natural history of the disease, except for tumors greater than 10 mm in largest dimension which are located anterior to the equator with fewer than 2 epithelioid cells per high power field. Findings suggest that uveal melanoma can be treated by means other than enucleation to allow a chance for prolonged survival with vision preservation.

Original languageEnglish (US)
Pages (from-to)481-487
Number of pages7
JournalJournal of Chronic Diseases
Volume37
Issue number6
DOIs
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Survival Analysis
Natural History
Survival
Epithelioid Cells
Neoplasms
Delayed Diagnosis
Age Distribution
Uveal melanoma
Population
Therapeutics

ASJC Scopus subject areas

  • Epidemiology

Cite this

A deficit survival analysis to assess the natural history of uveal melanoma. / Lavin, Philip T.; Albert, Daniel; Seddon, Johanna M.

In: Journal of Chronic Diseases, Vol. 37, No. 6, 01.01.1984, p. 481-487.

Research output: Contribution to journalArticle

Lavin, Philip T. ; Albert, Daniel ; Seddon, Johanna M. / A deficit survival analysis to assess the natural history of uveal melanoma. In: Journal of Chronic Diseases. 1984 ; Vol. 37, No. 6. pp. 481-487.
@article{cccb631fc4de4501b42caeaa2bc37921,
title = "A deficit survival analysis to assess the natural history of uveal melanoma",
abstract = "A deficit survival analysis was conducted using a retrospective series of 230 patients with uveal melanoma. All underwent enucleation as primary treatment for their disease. Considering the three leading prognostic factors (epithelioid cells per high power field, tumor size, and tumor location), median age was plotted against median survival to determine pathways of disease spread, local and metastatic disease phases, consequences of delayed diagnosis, and the timing of enucleation. The subgroup with all three factors favorable could be subdivided into younger and older subsets on the basis of a bimodal age distribution. Only the older subset could be identified as a local disease state where survival following enucleation corresponded to normal population survival. All remaining subgroups were metastatic because of survival deficits compared to the normal population. Disease tended to progress according to three well defined pathways with 6-8 years required to progress from one subgroup to the next along these paths. These pathways were characterized by constant deficit survivals, suggesting that delays in diagnosis did not translate into loss in survival. Moreover, the value of enucleation as primary therapy can be questioned in the context that it does not appear to alter the natural history of the disease, except for tumors greater than 10 mm in largest dimension which are located anterior to the equator with fewer than 2 epithelioid cells per high power field. Findings suggest that uveal melanoma can be treated by means other than enucleation to allow a chance for prolonged survival with vision preservation.",
author = "Lavin, {Philip T.} and Daniel Albert and Seddon, {Johanna M.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1016/0021-9681(84)90031-6",
language = "English (US)",
volume = "37",
pages = "481--487",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - A deficit survival analysis to assess the natural history of uveal melanoma

AU - Lavin, Philip T.

AU - Albert, Daniel

AU - Seddon, Johanna M.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - A deficit survival analysis was conducted using a retrospective series of 230 patients with uveal melanoma. All underwent enucleation as primary treatment for their disease. Considering the three leading prognostic factors (epithelioid cells per high power field, tumor size, and tumor location), median age was plotted against median survival to determine pathways of disease spread, local and metastatic disease phases, consequences of delayed diagnosis, and the timing of enucleation. The subgroup with all three factors favorable could be subdivided into younger and older subsets on the basis of a bimodal age distribution. Only the older subset could be identified as a local disease state where survival following enucleation corresponded to normal population survival. All remaining subgroups were metastatic because of survival deficits compared to the normal population. Disease tended to progress according to three well defined pathways with 6-8 years required to progress from one subgroup to the next along these paths. These pathways were characterized by constant deficit survivals, suggesting that delays in diagnosis did not translate into loss in survival. Moreover, the value of enucleation as primary therapy can be questioned in the context that it does not appear to alter the natural history of the disease, except for tumors greater than 10 mm in largest dimension which are located anterior to the equator with fewer than 2 epithelioid cells per high power field. Findings suggest that uveal melanoma can be treated by means other than enucleation to allow a chance for prolonged survival with vision preservation.

AB - A deficit survival analysis was conducted using a retrospective series of 230 patients with uveal melanoma. All underwent enucleation as primary treatment for their disease. Considering the three leading prognostic factors (epithelioid cells per high power field, tumor size, and tumor location), median age was plotted against median survival to determine pathways of disease spread, local and metastatic disease phases, consequences of delayed diagnosis, and the timing of enucleation. The subgroup with all three factors favorable could be subdivided into younger and older subsets on the basis of a bimodal age distribution. Only the older subset could be identified as a local disease state where survival following enucleation corresponded to normal population survival. All remaining subgroups were metastatic because of survival deficits compared to the normal population. Disease tended to progress according to three well defined pathways with 6-8 years required to progress from one subgroup to the next along these paths. These pathways were characterized by constant deficit survivals, suggesting that delays in diagnosis did not translate into loss in survival. Moreover, the value of enucleation as primary therapy can be questioned in the context that it does not appear to alter the natural history of the disease, except for tumors greater than 10 mm in largest dimension which are located anterior to the equator with fewer than 2 epithelioid cells per high power field. Findings suggest that uveal melanoma can be treated by means other than enucleation to allow a chance for prolonged survival with vision preservation.

UR - http://www.scopus.com/inward/record.url?scp=0021341622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021341622&partnerID=8YFLogxK

U2 - 10.1016/0021-9681(84)90031-6

DO - 10.1016/0021-9681(84)90031-6

M3 - Article

C2 - 6725501

AN - SCOPUS:0021341622

VL - 37

SP - 481

EP - 487

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 6

ER -